Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025
Lisata Therapeutics (LSTA), a clinical-stage pharmaceutical company focused on advanced solid tumor treatments, has scheduled its full year 2024 financial results announcement for Thursday, February 27, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern time to discuss the results and provide a business update.
Participants must pre-register for the conference call through a provided link. Registered attendees will receive dial-in details via email. To ensure smooth participation, attendees are encouraged to dial in 15 minutes before the scheduled start time. A live webcast will be available on Lisata's website under the Investors & News section, with a replay accessible for 12 months after the call.
Lisata Therapeutics (LSTA), un'azienda farmaceutica in fase clinica focalizzata su trattamenti avanzati per tumori solidi, ha programmato l'annuncio dei risultati finanziari per l'intero anno 2024 per giovedì 27 febbraio 2025, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica alle 16:30 ora orientale per discutere i risultati e fornire un aggiornamento sulle attività.
I partecipanti devono registrarsi in anticipo per la conferenza telefonica tramite un link fornito. Gli iscritti riceveranno i dettagli per la composizione via email. Per garantire una partecipazione fluida, si consiglia ai partecipanti di chiamare 15 minuti prima dell'orario di inizio previsto. Una diretta streaming sarà disponibile sul sito web di Lisata nella sezione Investitori & News, con una registrazione accessibile per 12 mesi dopo la chiamata.
Lisata Therapeutics (LSTA), una compañía farmacéutica en etapa clínica enfocada en tratamientos avanzados para tumores sólidos, ha programado el anuncio de sus resultados financieros del año completo 2024 para el jueves 27 de febrero de 2025, después del cierre del mercado. La compañía llevará a cabo una conferencia telefónica a las 4:30 p.m. hora del Este para discutir los resultados y proporcionar una actualización comercial.
Los participantes deben preinscribirse para la conferencia telefónica a través de un enlace proporcionado. Los asistentes registrados recibirán los detalles para la llamada por correo electrónico. Para asegurar una participación fluida, se recomienda a los asistentes que se conecten 15 minutos antes de la hora de inicio programada. Se dispondrá de una transmisión en vivo en el sitio web de Lisata en la sección de Inversores y Noticias, con una repetición accesible durante 12 meses después de la llamada.
리사타 제약 (LSTA), 고급 고형종양 치료에 중점을 둔 임상 단계 제약 회사는 2025년 2월 27일 목요일에 2024년 전체 재무 결과 발표를 시장 종료 후로 예정했습니다. 회사는 동부 표준시 오후 4시 30분에 결과를 논의하고 비즈니스 업데이트를 제공하기 위해 컨퍼런스 콜을 개최할 것입니다.
참가자는 제공된 링크를 통해 컨퍼런스 콜에 사전 등록해야 합니다. 등록된 참석자는 이메일로 다이얼인 세부 정보를 받게 됩니다. 원활한 참여를 보장하기 위해 참석자는 예정된 시작 시간 15분 전에 전화 접속을 권장합니다. 리사타 웹사이트의 투자자 및 뉴스 섹션에서 생중계가 제공되며, 통화 후 12개월 동안 다시 볼 수 있습니다.
Lisata Therapeutics (LSTA), une société pharmaceutique en phase clinique axée sur les traitements avancés des tumeurs solides, a prévu l'annonce de ses résultats financiers pour l'année complète 2024 pour le jeudi 27 février 2025, après la clôture du marché. La société organisera une conférence téléphonique à 16h30 heure de l'Est pour discuter des résultats et fournir une mise à jour sur les affaires.
Les participants doivent s'inscrire à l'avance pour la conférence téléphonique via un lien fourni. Les participants enregistrés recevront les détails de connexion par e-mail. Pour garantir une participation fluide, il est conseillé aux participants de se connecter 15 minutes avant l'heure de début prévue. Une diffusion en direct sera disponible sur le site Web de Lisata dans la section Investisseurs & Actualités, avec un replay accessible pendant 12 mois après l'appel.
Lisata Therapeutics (LSTA), ein pharmazeutisches Unternehmen in der klinischen Phase, das sich auf fortgeschrittene Behandlungen von soliden Tumoren konzentriert, hat die Bekanntgabe seiner finanziellen Ergebnisse für das gesamte Jahr 2024 für Donnerstag, den 27. Februar 2025, nach Börsenschluss angesetzt. Das Unternehmen wird um 16:30 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen und ein Update zum Geschäft zu geben.
Teilnehmer müssen sich im Voraus über einen bereitgestellten Link für die Telefonkonferenz registrieren. Registrierte Teilnehmer erhalten die Einwahldaten per E-Mail. Um eine reibungslose Teilnahme zu gewährleisten, wird den Teilnehmern geraten, 15 Minuten vor dem geplanten Beginn einzuwählen. Eine Live-Übertragung wird auf der Website von Lisata im Bereich Investoren & Nachrichten verfügbar sein, mit einer Wiederholung, die 12 Monate nach dem Anruf zugänglich ist.
- None.
- None.
BASKING RIDGE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the twelve months ended December 31, 2024, on Thursday, February 27, 2025, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.
Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details with dial-in options. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time.
A live webcast of the call will also be accessible under the Investors & News section of Lisata’s website and will be available for replay beginning two hours after the conclusion of the call for 12 months.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into the second quarter of 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. Learn more about certepetide’s mechanism of action in our short film. For more information on the Company, please visit www.lisata.com.
Contact:
Investors:
Lisata Therapeutics
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
Media:
ICR Healthcare
Elizabeth Coleman
Account Supervisor
Phone: 203-682-4783
Email: elizabeth.coleman@icrhealthcare.com
This press release was published by a CLEAR® Verified individual.
FAQ
When will Lisata Therapeutics (LSTA) release its full year 2024 financial results?
What time is Lisata Therapeutics (LSTA) earnings call on February 27, 2025?
How long will Lisata Therapeutics (LSTA) Q4 2024 earnings call replay be available?
How can investors join Lisata Therapeutics (LSTA) February 2025 earnings call?
